Article Text

PDF
PWE-049 Small-Bowel Capsule Endoscopy with 360° Panoramic-View: Results of The First Multicenter, Observational, Study
  1. GE Tontini1,
  2. F Wiedbrauck2,
  3. F Cavallaro3,
  4. R Marino4,
  5. L Spina5,
  6. ME McAlindon6,
  7. A Koulaouzidis7,
  8. E Rondonotti8,
  9. L Pastorelli9,
  10. M Vecchi5
  1. 1Gastroenterology & Digestive Endoscopy Unit, RCCS Policlinico San Donato, Milano, Italy
  2. 2Klinik für Gastroenterologie/GI-Onkologie, Allgemeines Krankenhaus Celle, Celle, Germany
  3. 3Gastroenterology & Digestive Endoscopy Unit, IRCCS Policlinico San Donato, Milano
  4. 4Gastroenterology & Digestive Endoscopy Unit, AO Lodi, Lodi
  5. 5Gastroenterology & Digestive Endoscopy Unit, IRCCS Policlinico San Donato, Milano, Italy
  6. 6Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield
  7. 7Centre for Liver & Digestive Disorders, The Royal Infirmary of Edinburgh, Edinburgh, UK
  8. 8Gastroenterology Department, Ospedale Valcuce, Como
  9. 9IRCCS Policlinico San Donato, Milano, Italy

Abstract

Introduction CapsoCam®SV (CapsoVision Inc, Saratoga, USA) is a new small bowel capsule (SBC) with “panoramic view”, wire-free technology, and a long-lasting battery life. It is equipped with 4 high-frame rate cameras resulting in a high number of acquired frames. In previous studies, CapsoCam®SV showed comparable operative and diagnostic performance with frontal view SBCs.1,2

Methods First multicenter study to assess the performance of CapsoCam®SV1 and SV2. Between January 2011 and November 2015, all consecutive patients undergoing SBC with CapsoCam® in 4 Italian, 2 British, and 1 German Institution(s) were included. Findings were classified according to their clinical significance, in line with Saurin classification, as P0: low probability; P1: intermediate probability; P2: high probability.3 We defined SBC as “positive” when at least one P2 finding was identified.

Results We enrolled 172 patients (94 M; median age±SD: 68±17 years, range: 9–97 years). Of them, 142 were referred for obscure GI bleeding (32 overt/110 occult OGIB) and 28 for suspected (17) or established (2) Crohn’s disease (CD). Median battery life was 16.4 h (range 3.7–23.4 h). System failure occurred in 4 (2%) cases for technical problems; incomplete enteroscopy in 16/168 (9%), including two structuring disorders (i.e. stricturing CD & SB adenocarcinoma) with spontaneous capsule excretion and one stricturing SB carcinoid with capsule retrieval at time of surgery.The ampulla of Vater was clearly identified in 34% cases. The overall diagnostic yield (DY; rate of positive tests) was 41%; 43% in OGIB and 30% in suspected CD. In a per-lesion analysis, overall 560 findings were detected (P0: 55, P1: 253, P2: 252). Most lesions were located in the small bowel (448/560: 80%); 48% of them were P2. Interestingly, 95/560 (17%) and 17/560 (3%) lesions were detected in the upper and in the lower GI tract, 34 and 12 of them being classified as P2, respectively.

Conclusion The first multicenter study conducted in the everyday clinical practice with CapsoCam®SV, and based on the largest series so far collected, showed that SBC with 360° panoramic-view is easy to use, reliable, and has comparable DY and safety profile to forward view SCE.

References 1 Friedrich K, et al. J Gastroenterol Hepatol 2013;28(9):1496–501.

2 Pioche M, et al. Endoscopy 2014;46(6):479–84.

3 Saurin JC, et al. Endoscopy 2003;35(7):576–84.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.